PSTV Plus Therapeutics

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers.

Company profile

Marc Hedrick
Fiscal year end
Former names
IRS number

PSTV stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


21 Oct 21
28 Oct 21
31 Dec 21
Quarter (USD)
Sep 21 Jun 21 Mar 21 Dec 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.28M 21.28M 21.28M 21.28M 21.28M 21.28M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.17M 995.67K 750.33K 906.67K
Cash used (since last report) n/a n/a 1.12M 953.69K 718.7K 868.45K
Cash remaining n/a n/a 20.16M 20.33M 20.56M 20.41M
Runway (months of cash) n/a n/a 17.3 20.4 27.4 22.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
27 Oct 21 Petersen Greg Common Stock Buy Acquire P No No 1.72 12,500 21.5K 32,500
26 Oct 21 Hedrick Marc H Common Stock Buy Acquire P No No 1.6599 2,500 4.15K 21,080
26 Oct 21 Andrew John Hugh MacIntyre Sims Common Stock Buy Acquire P No No 1.6694 2,000 3.34K 6,230
13 Sep 21 Robert P Lenk Common Stock Buy Acquire P No No 1.8587 7,000 13.01K 10,000
28 Jul 21 Andrew John Hugh MacIntyre Sims Common Stock Buy Acquire P No No 1.9099 2,244 4.29K 4,230
27 Jul 21 Andrew John Hugh MacIntyre Sims Common Stock Buy Acquire P No No 2.05 1,986 4.07K 1,986

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

17.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 23 19 +21.1%
Opened positions 9 17 -47.1%
Closed positions 5 1 +400.0%
Increased positions 5 0 NEW
Reduced positions 2 0 NEW
13F shares
Current Prev Q Change
Total value 5.19M 1.79M +189.9%
Total shares 2.14M 830.19K +157.6%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Vanguard 712.85K $1.83M +824.7%
Intracoastal Capital 300K $606K 0.0%
NanoTx 230.77K $466K 0.0%
Two Sigma Advisers 175.5K $449K +186.8%
BLK Blackrock 159.86K $410K +32.1%
Geode Capital Management 130.79K $334K NEW
Two Sigma Investments 108.52K $278K NEW
VIRT Virtu Financial 76.19K $195K NEW
Dimensional Fund Advisors 68.43K $175K NEW
Citadel Advisors 43.53K $111K NEW
Largest transactions
Shares Bought/sold Change
Vanguard 712.85K +635.76K +824.7%
Geode Capital Management 130.79K +130.79K NEW
Two Sigma Advisers 175.5K +114.3K +186.8%
Two Sigma Investments 108.52K +108.52K NEW
VIRT Virtu Financial 76.19K +76.19K NEW
Dimensional Fund Advisors 68.43K +68.43K NEW
Citadel Advisors 43.53K +43.53K NEW
NTRS Northern Trust 40.52K +40.52K NEW
BLK Blackrock 159.86K +38.82K +32.1%
STT State Street 34.21K +34.21K NEW

Financial report summary

  • The report of our independent registered public accounting firm contains an emphasis paragraph regarding the substantial doubt about our ability to continue as a “going concern.”
  • Our operating results have been and will likely continue to be volatile.
  • Our current business strategy is high-risk and may not be successful.
  • We face intense competition, and if our competitors market or develop products that are marketed more effectively, approved more quickly than our product candidates, or demonstrated to be safer or more effective than our product candidates, our commercial opportunities could be reduced or eliminated.
  • Our current and future clinical trials may fail to demonstrate acceptable levels of safety and efficacy for our product candidates, which could prevent or significantly delay their regulatory approval and commercialization, which would have a material and adverse impact on our business.
  • We may have difficulty enrolling, or fail to enroll patients, in our clinical trials, which could delay or prevent clinical trials of our drug candidates.
  • Our success depends in substantial part on our ability to obtain regulatory approvals for our RNL product candidate. However, we cannot be certain that we will receive regulatory approval for this product candidate or our other product candidates.
  • If our product candidates and technologies receive regulatory approval but do not achieve broad market acceptance, especially by physicians, the revenue that we generate will be limited.
  • All potential applications of our product candidates are pre-commercial, which subjects us to development and marketing risks.
  • If we or any party to a key collaboration, licensing, development, acquisition or similar arrangement fails to perform material obligations, or commit a breach, under such arrangement, or any arrangement is terminated for any reason, there could be an adverse effect on our business.
  • If we or collaborators fail to comply with regulatory requirements applicable to the development, manufacturing, and marketing of our product candidates, regulatory agencies may take action against us or them, which could significantly harm our business.
  • Changing, new and/or emerging government regulations, including healthcare legislative reform measures, may adversely affect us.
  • Orphan drug designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug designation or other regulatory exclusivity for some of our product candidates, our competitive position would be harmed.
  • If we experience an interruption in supply from a material sole source supplier, our business may be harmed
  • We may engage in strategic transactions that could impact our liquidity, increase our expenses, and present significant distractions to our management.
  • We must maintain quality assurance certification and manufacturing approvals.
  • If we are unable to identify, hire and/or retain key personnel, or if any of our personnel were to test positive for COVID-19, we may not be able to sustain or grow our business.
  • We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.
  • A failure to adequately protect private health information could result in severe harm to our reputation and subject us to significant liabilities, each of which could have a material adverse effect on our business.
  • We and our collaborators must comply with environmental laws and regulations, including those pertaining to use of hazardous and biological materials in our business, and failure to comply with these laws and regulations could expose us to significant liabilities.
  • We may not be able to protect our trade secrets.
  • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
  • We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights, and we may be unable to protect our rights to our product candidates and technology.
  • If we are sued for infringing intellectual property rights of third parties, it will be costly and time consuming, and an unfavorable outcome in that litigation would have a material adverse effect on our business.
  • Future sales of our common stock may depress our share price.
  • The market price of our common stock may be volatile and fluctuate significantly, which could result in substantial losses for stockholders.
  • We may be or become the target of securities litigation, which is costly and time-consuming to defend.
  • We may issue debt and equity securities or securities convertible into equity securities, any of which may be senior to our common stock as to distributions and in liquidation, which could negatively affect the value of our common stock.
  • We could be delisted from Nasdaq, which would seriously harm the liquidity of our stock and our ability to raise capital.
  • Our charter documents contain anti-takeover provisions.
  • We presently do not intend to pay cash dividends on our common stock.
  • If securities and/or industry analysts fail to continue publishing research about our business, if they change their recommendations adversely, or if our results of operations do not meet their expectations, our stock price and trading volume could decline.
  • The COVID-19 pandemic could adversely affect our business, results of operations, and financial condition.
  • We may face business disruption and related risks resulting from the COVID-19 pandemic and the invocation of the Defense Production Act, either of which could have a material adverse effect on our business.
  • Increased information technology security threats and more sophisticated and targeted computer crime could pose a risk to our systems, networks, and products.
Management Discussion
  • Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations
  • Plus Therapeutics is a U.S. pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers.  Plus’ investigational drugs are intended for both adult and pediatric patients on a worldwide basis. Plus Therapeutics’ headquarters and manufacturing facility are in Texas, in close proximity to world-class cancer institutions and researchers. Our dedicated team of engineers, physicians, scientists, and other professionals are committed to advancing our novel radiotherapeutic technology for the benefit of cancer patients and healthcare providers. Plus’ technology includes nanoliposome-encapsulated, BMEDA-chelated Rhenium-186 radiotherapeutics.  The nanoliposomes facilitate local and precise drug delivery and improved drug retention at the target site while Rhenium-186 releases high-energy beta particles for treatment and gamma photons for imaging.  This radiotherapeutic platform, combined with advances in surgery, nuclear medicine, and radiation oncology, affords us the opportunity to treat multiple types of cancer.  Our current pipeline is focused on treating rare and central nervous system tumors with significant unmet medical needs.
  • Plus Therapeutics’ lead investigational drug, Rhenium-186 NanoLiposome (186RNL), is a patented radiotherapy potentially useful for patients with recurrent glioblastoma (GBM).  The RNL technology was part of a licensed radiotherapeutic portfolio that we acquired from NanoTx, Corp. (“NanoTx”) on May 7, 2020. The licensed radiotherapeutic can be applied toward several cancer targets, and has an active $3.0 million award from U.S. National Institutes of Health/National Cancer Institute which will provide financial support for the continued clinical development of 186RNL for recurrent glioblastoma through the completion of a Phase 2 clinical trial and enrollment of up to 55 patients.
Content analysis
H.S. sophomore Avg
New words: accrual, adult, announced, breast, burden, clearance, complication, cord, decision, dedicated, endpoint, growing, incidence, IND, intrathecal, LM, LPC, lung, motion, opportunity, opposition, proximity, responded, retention, sequential, shown, site, spinal, surgery, system, toxicity, ventricle
Removed: decreased, established, financially, higher, mechanism, nanotechnology, rGBM, scale